References
- Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2024. [cited 2024 Feb 1]. Available at:
https://gco.iarc.who.int/today - Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022; 400: 1345–62. doi: 10.1016/S0140-6736(22)01200-4
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182–236. doi: 10.1016/j.jhep.2018.03.019
- Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76: 681–93. doi: 10.1016/j.jhep.2021.11.018
- Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open 2023; 8: 101567. doi: 10.1016/j.esmoop.2023.101567
- Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 2019; 72: 28–36. doi: 10.1016/j.ctrv.2018.11.002
- Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474–81. doi: 10.1016/j.jhep.2006.10.020
- Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinon A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 2010; 33: 41–52. doi: 10.1007/s00270-009-9711-7
- Boulin M, Guiu S, Chauffert B, Delhom E, Schmitt A, Hillon P, et al. Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anticancer Drugs 2011; 22: 741–8. doi: 10.1111/apt.12746
- Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 1993; 24: 275–88. doi: 10.2165/00003088-199324040-00002
- Guiu B, Hincapie G, Thompson L, Wu Y, Boulin M, Cassinotto C, et al. An in vitro evaluation of four types of drug-eluting embolics joaded with idarubicin. J Vasc Interv Radiol 2019: 30: 1303–9. doi: 10.1016/j.jvir.2018.12.022
- Favelier S, Boulin M, Hamza S, Cercueil JP, Cherblanc V, Lepage C, et al. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: First experience. Cardiovasc Intervent Radiol 2013; 36: 1039–46. doi: 10.1007/s00270-012-0532-8
- Guiu B, Schmitt A, Reinhardt S, Deltenre P, Denys A, Lepida A, et al. Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics. J Vasc Interv Radiol 2015; 26: 262–70. doi: 10.1016/j.jvir.2014.08.021
- Boulin M, Hillon P, Cercueil JP, Raoul JL, Lepage C, Barbare JC, et al. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther 2014; 39: 1301–13. doi: 10.1111/apt.12776
- Guiu B, Chevallier P, Assenat E, Barbier E, Merle P, Bouvier A, et al. Idarubicin-loaded beads for chemoembolization of hepatocellular carcinoma: the IDASPHERE II single-arm phase II trial 2019; 291: 801–8. doi: 0.1148/radiol.2019182399
- Guiu B, Jouve JL, Schmitt A, Minello A, Bonnetain F, Cassinotto C, et al. Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: the LIDA-B phase I trial. J Hepatol 2018; 68: 1163–71. doi: 10.1016/j.jhep.2018.01.022.
- Common Terminology Criteria for Adverse Events v. 5.0 [internet]. [cited 2024 Jan 3]. Available at:
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf - Lencioni R, Llovet J. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52–60. doi: 10.1055/s-0030-1247132
- Guiu B, Hincapie G, Thompson L, Wu Y, Boulin M, Cassinotto C, et al. An in vitro evaluation of four types of drug-eluting embolics loaded with idarubicin. J Vasc Interv Radiol 2019; 30: 1303–9. doi: 10.1016/j.jvir.2018.12.022.
- de Baere T, Guiu B, Ronot M, Chevallier P, Sergent G, Tancredi I, et al. Real life prospective evaluation of new drug-eluting platform for chemoembolization of patients with hepatocellular carcinoma: PARIS registry. Cancers 2020; 12: 3405. doi: 10.3390/cancers12113405
- Guiu B, Colombat S, Piron L, Hermida M, Allimant C, Pierredon-Foulongne MA, et al. Transarterial chemoembolization of hepatocellular carcinoma with idarubicin-loaded tandem drug-eluting embolics. Cancers 2019; 11: 987. doi: 10.3390/cancers11070987
- Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995; 13: 2827–34. doi: 10.1200/JCO.1995.13.11.2827
- Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, et al. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. J Hepatol 2012; 56: 609–17. doi: 10.1016/j.jhep.2011.09.012
- Shi Z, Wang D, Jiang H, Kang T, Yi R, Cui L. Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial. Radiol Oncol 2023; 57: 70–9. doi: 10.2478/raon-2023-0001
- Korsic S, Levasic N, Dezman R, Zupan LAL, Trotovsek B, Jansa R, et al. Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma. Radiol Oncol 2022; 56: 311–8. doi: 10.2478/raon-2022-0019
- Gomes FV, Oliveira JA, Correia MT, Costa NV, Abrantes J, Torres D, et al. Chemoembolization of hepatocellular carcinoma with drug-eluting polyethylene glycol embolic agents: single-center retrospective analysis in 302 patients. J Vasc Interv Radiol 2018; 29: 841–9. doi: 10.1016/j.jvir.2018.02.004
- Lucatelli P, Ginnani Corradini L, De Rubeis G, Corona M, Saba L, Catalano C, et al. Balloon-occluded transcatheter arterial chemoembolization (b-TACE) for hepatocellular carcinoma performed with polyethylene-glycol epirubicin-loaded drug-eluting embolics: safety and preliminary results. Cardiovasc Intervent Radiol 2019; 42: 853–62. doi: 10.1007/s00270-019-02192-y
- Aliberti C, Carandina R, Sarti D, Mulazzani L, Pizzirani E, Guadagni S, et al. Chemoembolization adopting polyethylene glycol drug-eluting embolics loaded with doxorubicin for the treatment of hepatocellular carcinoma. AJR Am J Roentgenol 2017; 209: 430–4. doi: 10.2214/AJR.16.17477
- Fiorentini G, Sarti D, Carandina R, Mincarelli C, Candelari R, Argirò R, et al. A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma. Future Oncol 2019; 15: 695–703. doi: 10.2217/fon-2018-0425
- Veloso Gomes F, de Baère T, Verset G, Coimbra É, Tovar-Felice G, Malagari K, et al. Transarterial chemoembolization with anthracyclines-loaded polyethylene glycol drug eluting microspheres for the treatment of hepatocellular carcinoma: a pooled multicentric analysis of survival in 580 patients. Cardiovasc Intervent Radiol 2023; 46: 436–46. doi: 10.1007/s00270-023-03362-9
- Popovic P, Stabuc B, Jansa R, Garbajs M. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under conebeam computed tomography control. Radiol Oncol 2016; 50: 418–26. doi: 10.1515/raon-2015-0045
- Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv238–55. doi: 10.1093/annonc/mdy308
- Bruix J, Reig M, Rimola J, Vilana R, Burrel M, Llovet JM, et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 2011; 54: 2238–44. doi: 10.1002/hep.24670
- Wang H, Li B, Wang Y, Zhang J, Wu Y, Fan W, Li J. Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization. J Cancer Res Ther 2020; 16: 301–8. doi: 10.4103/jcrt.JCRT_898_19